Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014, 158(4):511-517 | DOI: 10.5507/bp.2014.004

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Jan M. Horaceka,b, Martina Vasatovac, Radek Pudild, Milos Tichyc, Pavel Zakb, Martin Jakla,d, Ladislav Jebavya,b, Jaroslav Malyb
a Department of Internal Medicine, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
b 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove
c Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove
d 1st Department of Internal Medicine - Cardioangiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove

Background: Cardiotoxicity is a well-known and potentially serious complication of anticancer therapy. Anthracycline-based chemotherapy represents the greatest risk. Early detection of cardiotoxicity is crucial for applying preventive and supportive therapeutic strategies.

Methods and Results: Various methods have been recommended for monitoring of cardiotoxicity. In our conditions, echocardiography and electrocardiography are routinely used. However, this approach shows low sensitivity for the early prediction of cardiomyopathy when the possibilities of appropriate management could still improve the patient's outcome. Recently, biomarkers of cardiac injury have been investigated in the assessment of chemotherapy-induced cardiotoxicity. Cardiospecific biomarkers, such as cardiac troponins, show high diagnostic efficacy in the early subclinical phase of the disease before the clinical onset of cardiomyopathy. Increase in their concentrations correlates with disease severity. As for natriuretic peptides, some studies, including ours, have shown promising results. Definitive evidence of their diagnostic and prognostic role in this context is still lacking and natriuretic peptides have not been routinely used for monitoring of cardiotoxicity in clinical practice. Other perspective biomarkers of cardiotoxicity in oncology are under study, especially heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB). Our studies using GPBB have provided encouraging results. However, the available data are limited and their practical use in this context cannot be recommended until their clinical efficacy is clearly defined.

Conclusions: This review covers the current status of biomarkers for the early detection of anthracycline-induced cardiotoxicity. The authors present in brief, their own experience with multiple biomarkers in the detection of cardiotoxicity.

Keywords: biomarkers, cardiotoxicity, anthracyclines, chemotherapy

Received: July 7, 2013; Accepted: January 15, 2014; Prepublished online: January 23, 2014; Published: December 9, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horacek, J.M., Vasatova, M., Pudil, R., Tichy, M., Zak, P., Jakl, M., Jebavy, L., & Maly, J. (2014). Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status. Biomedical papers, 158(4), 511-517. doi: 10.5507/bp.2014.004
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58. Go to original source... Go to PubMed...
    2. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006;5:791-809. Go to original source... Go to PubMed...
    3. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010;53:105-13. Go to original source... Go to PubMed...
    4. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37:300-11. Go to original source... Go to PubMed...
    5. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005;35:323-34. Go to original source... Go to PubMed...
    6. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation 2004;109:3122-31. Go to original source... Go to PubMed...
    7. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302. Go to original source... Go to PubMed...
    8. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5. Go to original source... Go to PubMed...
    9. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective blinded long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699-709. Go to original source... Go to PubMed...
    10. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43. Go to original source... Go to PubMed...
    11. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005;131:561-78. Go to original source... Go to PubMed...
    12. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002;4:235-42. Go to original source... Go to PubMed...
    13. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin induced cardiomyopathy. Oncology 1996;53:461-70. Go to original source... Go to PubMed...
    14. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, Sandor G, Benson L, Williams R. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992;89:942-9. Go to original source... Go to PubMed...
    15. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994;93:433-7. Go to original source... Go to PubMed...
    16. Ritchie JL, Bateman TM, Bonow RO, Crawford MH, Gibbons RJ, Hall RJ, O'Rourke RA, Parisi AF, Verani MS. Guidelines for clinical use of cardiac radionuclide imaging: report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures, in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995;25:521-47. Go to original source... Go to PubMed...
    17. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10:132-9. Go to original source... Go to PubMed...
    18. Sabel MS, Levine EG, Hurd T, Schwartz GN, Zielinski R, Hohn D, Edge SB. Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Am J Clin Oncol 2001;24:425-8. Go to original source... Go to PubMed...
    19. Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol 2012;19:377-88. Go to original source... Go to PubMed...
    20. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-20. Go to original source... Go to PubMed...
    21. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999;25:237-47. Go to original source... Go to PubMed...
    22. Benvenuto GM, Ometto R, Fontanelli A, Fortunato A, Ruffini PA, Fosser V, Morandi P. Chemotherapy-related cardiotoxicity: new diagnostic and preventive strategies. Ital Heart J 2003;4:655-67. Go to original source...
    23. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002;25:301-11. Go to original source... Go to PubMed...
    24. Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Mazurova Y, Gersl V. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005;4:457-72. Go to original source... Go to PubMed...
    25. Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007;43:1959-66. Go to original source... Go to PubMed...
    26. Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol 2008;25:655-64. Go to original source... Go to PubMed...
    27. Urbanova D, Urban L, Danova K, Simkova I. Natriuretic peptides: biochemical markers of anthracycline cardiac toxicity? Oncol Res 2008;17:51-58. Go to original source... Go to PubMed...
    28. Morandi P, Ruffini PA, Benvenuto GM, Raimondi R, Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005;35:323-34. Go to original source... Go to PubMed...
    29. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX, Ferrans VJ. Correlation between serum levels of cardiac troponin T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999;17:2237-43. Go to original source... Go to PubMed...
    30. Koh E, Nakamura T, Takahashi H. Troponin T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 2004;68:163-7. Go to original source... Go to PubMed...
    31. Kral M, Skoloudik D, Sanak D, Veverka T, Bartkova A, Dornak T, Hutyra M, Vindis D, Ulehlova J, Slavik L, Svabova M, Kubickova V, Herzig R, Kanovsky P. Assessment of relationship between acute ischemic stroke and heart disease - protocol of a prospective observational trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156:284-9. Go to original source... Go to PubMed...
    32. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13:1-10. Go to original source... Go to PubMed...
    33. Wallace KB, Hausner E, Herman E, Holt GD, MacGregor JT, Metz AL, Murphy E, Rosenblum IY, Sistare FD, York MJ. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004;32:106-21. Go to original source... Go to PubMed...
    34. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-22. Go to original source... Go to PubMed...
    35. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, Cinieri S, Martinelli G, Fiorentini C, Cipolla CM. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13:710-5. Go to original source... Go to PubMed...
    36. Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, Martinelli G, Cipolla CM. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003;49:248-52. Go to original source... Go to PubMed...
    37. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003;82:218-22. Go to original source... Go to PubMed...
    38. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-54. Go to original source... Go to PubMed...
    39. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. The effects of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351:145-53. Go to original source... Go to PubMed...
    40. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik I, Kes S, Tekuzman G. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005;16:798-804. Go to original source... Go to PubMed...
    41. Horacek JM, Pudil R, Tichy M, Jebavy L, Strasova A, Ulrychova M, Zak P, Maly J. Cardiac troponin I seems to be superior to cardiac troponin T in the early detection of cardiac injury associated with anthracycline treatment. Onkologie 2008;31:559-60. Go to original source... Go to PubMed...
    42. Auner HW, Tinchon C, Quehenberger F, Linkesch W, Sill H. Troponins in prediction of cardiotoxic effects. Lancet 2001;357:808. Go to original source... Go to PubMed...
    43. Cardinale D, Lamantia G, Cipolla CM. Troponin I and cardiovascular risk stratification in patients with testicular cancer. J Clin Oncol 2006;24:3508-14. Go to original source... Go to PubMed...
    44. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: Systematic review of the literature and recommendations for use. Am J Clin Pathol 2008;130:688-95. Go to original source... Go to PubMed...
    45. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847. Go to original source... Go to PubMed...
    46. Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007;53:813-22. Go to original source... Go to PubMed...
    47. Kotaska K, Prusa R. Evidence for natriuretic peptides A and B as non-invasive markers in congenital and valvular heart disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010;154:21-4. Go to original source... Go to PubMed...
    48. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G. Clinical application of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-8. Go to original source... Go to PubMed...
    49. Hess G, Runkel S, Zdunek D, Hitzler WE. N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease. Clin Lab 2005;51:167-72. Go to PubMed...
    50. Bauch M, Ester A, Kimura B, Victorica BE, Kedar A, Phillips MI. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992;69:1492-7. Go to original source... Go to PubMed...
    51. Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, Kurabayashi M, Yamaoki K, Mitani K, Hirai H, Nagai R, Yazaki Y. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362-3. Go to original source... Go to PubMed...
    52. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4-9. Go to original source... Go to PubMed...
    53. Erkus B, Demirtas S, Yarpuzlu AA, Can M, Genc Y, Karaca L. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr 2007;96:506-9. Go to original source... Go to PubMed...
    54. Ekstein S, Nir A, Rein AJ, Perles Z, Bar-Oz B, Salpeter L, Algur N, Weintraub M. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 2007;29:440-4. Go to original source... Go to PubMed...
    55. Horacek JM, Pudil R, Tichy M, Jebavy L, Strasova A, Praus R, Zak P, Maly J. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005;52:430-4. Go to PubMed...
    56. Horacek JM, Pudil R, Jebavy L, Tichy M, Zak P, Maly J. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 2007;29:309-13.
    57. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005;51:1405-10. Go to original source... Go to PubMed...
    58. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, Hart DN. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000;26:309-13. Go to original source... Go to PubMed...
    59. Niwa N, Watanabe E, Hamaguchi M, Kodera Y, Miyazaki H, Kodama I, Ohono M. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001;80:460-5. Go to original source... Go to PubMed...
    60. Horacek JM, Pudil R, Tichy M, Jebavy L, Zak P, Slovacek L, Maly J. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp Oncol 2007;29:243-7.
    61. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkiö M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003;21:2349-56. Go to original source... Go to PubMed...
    62. Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, Hesse B, Kjaer A. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005;7:87-93. Go to original source... Go to PubMed...
    63. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999;62:135-41. Go to original source... Go to PubMed...
    64. Okumura H, Iuchi K, Yoshida T, Nakamura S, Takeshima M, Takamatsu H, Ikeno A, Usuda K, Ishikawa T, Ohtake S, Matsuda T. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000;104:158-63. Go to original source... Go to PubMed...
    65. Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005;26:1197-1202. Go to PubMed...
    66. Roziakova L, Bojtarova E, Mistrik M, Dubrava J, Gergel J, Lenkova N, Mladosievicova B. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res 2012;31:13. Go to original source... Go to PubMed...
    67. Pongprot Y, Sittiwangkul R, Charoenkwan P, Silvilairat S. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer. J Pediatr Hematol Oncol 2012;34:589-95. Go to original source... Go to PubMed...
    68. Peetz D, Post F, Schinzel H, Schweigert R, Schollmayer C, Steinbach K, Dati F, Noll F, Lackner KJ. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005;43:1351-8. Go to original source... Go to PubMed...
    69. Stejskal D, Lacnak B, Jedelsky L, Stepanova L, Proskova J, Solichova P, Kadalova L, Janosova M, Seitlova P, Karpisek M, Sprongl L. Use of glycogen phosphorylase BB measurement with POCT in the diagnosis of acute coronary syndromes. A comparison with the ELISA method. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007;151:247-9. Go to original source... Go to PubMed...
    70. O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 2006;114:550-7. Go to original source... Go to PubMed...
    71. Shortt CR, Worster A, Hill SA, Kavsak PA. Comparison of hs-cTnI, hs-cTnT, hFABP and GPBB for identifying early adverse cardiac events in patients presenting within six hours of chest pain-onset. Clin Chim Acta 2013;419:39-41. Go to original source... Go to PubMed...
    72. ElGhandour AH, ElSorady M, Azab S, ElRahman M. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematology Reviews 2009;1:29-32. Go to original source...
    73. Horacek JM, Tichy M, Jebavy L, Ulrychova M, Pudil R. Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation. Ann Oncol 2007;18:2041. Go to original source... Go to PubMed...
    74. Horacek JM, Tichy M, Jebavy L, Pudil R, Ulrychova M, Maly J. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia. Exp Oncol 2008;30:157-9.
    75. Horacek JM, Tichy M, Pudil R, Jebavy L. Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. Ann Oncol 2008;19:1656-7. Go to original source... Go to PubMed...
    76. Horacek JM, Tichy M, Pudil R, Jebavy L, Zak P, Ulrychova M, Slovacek L, Maly J. Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation. Neoplasma 2008;55:532-7. Go to original source...
    77. Horacek JM, Jebavy L, Ulrychova M, Tichy M, Pudil R, Zak P, Maly J. Glycogen phosphorylase BB could be a new biomarker for detection of cardiac toxicity during hematopoietic cell transplantation for hematological malignancies. Bone Marrow Transplant 2010;45:1123-4. Go to original source... Go to PubMed...
    78. Horacek JM, Vasatova M, Tichy M, Pudil R, Jebavy L, Maly J. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol 2010;32:97-99.
    79. Mercuro G, Cadeddu C, Piras A, Dessì M, Madeddu C, Deidda M, Serpe R, Massa E, Mantovani G. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2007;12:1124-33. Go to original source... Go to PubMed...
    80. Mantovani G, Madeddu C, Cadeddu C, Dessì M, Piras A, Massa E, Serpe R, Antoni G, Mercuro G. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 2008;13:1296-1305. Go to original source... Go to PubMed...
    81. Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, van den Berg MP, Burgerhof JG, Hoekstra HJ, Sluiter WJ, Gietema JA. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004;40:701-6. Go to original source... Go to PubMed...
    82. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008;112:1949-53. Go to original source... Go to PubMed...
    83. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10:391-9. Go to original source... Go to PubMed...

    Return to the content